Skip to main content
Top
Published in: BMC Infectious Diseases 1/2023

Open Access 01-12-2023 | SARS-CoV-2 | Research

Understanding metabolic alterations after SARS-CoV-2 infection: insights from the patients’ oral microenvironmental metabolites

Authors: Shengli Ma, Lijun Yang, Hui Li, Xinghe Chen, Xiaoyu Lin, Wenyu Ge, Yindong Wang, Liping Sun, Guiping Zhao, Bing Wang, Zheng Wang, Meng Wu, Xin Lu, Muhammad Luqman Akhtar, Depeng Yang, Yan Bai, Yu Li, Huan Nie

Published in: BMC Infectious Diseases | Issue 1/2023

Login to get access

Abstract

Background

Coronavirus disease 2019 is a type of acute infectious pneumonia and frequently confused with influenza since the initial symptoms. When the virus colonized the patient's mouth, it will cause changes of the oral microenvironment. However, few studies on the alterations of metabolism of the oral microenvironment affected by SARS-CoV-2 infection have been reported. In this study, we explored metabolic alterations of oral microenvironment after SARS-CoV-2 infection.

Methods

Untargeted metabolomics (UPLC-MS) was used to investigate the metabolic changes between oral secretion samples of 25 COVID-19 and 30 control participants. To obtain the specific metabolic changes of COVID-19, we selected 25 influenza patients to exclude the metabolic changes caused by the stress response of the immune system to the virus. Multivariate analysis (PCA and PLS-DA plots) and univariate analysis (students’ t-test) were used to compare the differences between COVID-19 patients and the controls. Online hiplot tool was used to perform heatmap analysis. Metabolic pathway analysis was conducted by using the MetaboAnalyst 5.0 web application.

Results

PLS-DA plots showed significant separation of COVID-19 patients and the controls. A total of 45 differential metabolites between COVID-19 and control group were identified. Among them, 35 metabolites were defined as SARS-CoV-2 specific differential metabolites. Especially, the levels of cis-5,8,11,14,17-eicosapentaenoic acid and hexanoic acid changed dramatically based on the FC values. Pathway enrichment found the most significant pathways were tyrosine-related metabolism. Further, we found 10 differential metabolites caused by the virus indicating the body’s metabolism changes after viral stimulation. Moreover, adenine and adenosine were defined as influenza virus-specific differential metabolites.

Conclusions

This study revealed that 35 metabolites and tyrosine-related metabolism pathways were significantly changed after SARS-CoV-2 infection. The metabolic alterations of oral microenvironment in COVID-19 provided new insights into its molecular mechanisms for research and prognostic treatment.
Appendix
Available only for authorised users
Literature
21.
Metadata
Title
Understanding metabolic alterations after SARS-CoV-2 infection: insights from the patients’ oral microenvironmental metabolites
Authors
Shengli Ma
Lijun Yang
Hui Li
Xinghe Chen
Xiaoyu Lin
Wenyu Ge
Yindong Wang
Liping Sun
Guiping Zhao
Bing Wang
Zheng Wang
Meng Wu
Xin Lu
Muhammad Luqman Akhtar
Depeng Yang
Yan Bai
Yu Li
Huan Nie
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2023
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07979-y

Other articles of this Issue 1/2023

BMC Infectious Diseases 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine